JAK2 and acquired polycythemia vera: Further analyses of these cohorts show that patients with JAK2 mutated before TET2 are younger at presentation of the disease in clinics, are more likely to present with PV, have a higher risk of thrombosis, and respond better to JAK2 inhibitor ruxolitinib.